Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance

Citations Over TimeTop 10% of 2015 papers

Abstract

Resistance to platinum-based chemotherapy is the major barrier to treating epithelial ovarian cancer. To improve patient outcomes, it is critical to identify the underlying mechanisms that promote platinum resistance. Emerging evidence supports the concept that platinum-based therapies are able to eliminate the bulk of differentiated cancer cells, but are unable to eliminate cancer initiating cells (CIC). To date, the relevant pathways that regulate ovarian CICs remain elusive. Several correlative studies have shown that Wnt/β-catenin pathway activation is associated with poor outcomes in patients with high-grade serous ovarian cancer (HGSOC). However, the functional relevance of these findings remain to be delineated. We have uncovered that Wnt/β-catenin pathway activation is a critical driver of HGSOC chemotherapy resistance, and targeted inhibition of this pathway, which eliminates CICs, represents a novel and effective treatment for chemoresistant HGSOC. Here we show that Wnt/β-catenin signaling is activated in ovarian CICs, and targeted inhibition of β-catenin potently sensitized cells to cisplatin and decreased CIC tumor sphere formation. Furthermore, the Wnt/β-catenin specific inhibitor iCG-001 potently sensitized cells to cisplatin and decreased stem-cell frequency in platinum resistant cells. Taken together, our data is the first report providing evidence that the Wnt/β-catenin signaling pathway maintains stem-like properties and drug resistance of primary HGSOC PDX derived platinum resistant models, and therapeutic targeting of this pathway with iCG-001/PRI-724, which has been shown to be well tolerated in Phase I trials, may be an effective treatment option.

Related Papers

• → Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy(1991)196 cited
• → Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study(2019)19 cited
• THE COMPARISION OF STUDY BETWEEN CISPLATIN AND CARBOPLATIN IN CHEMOTHERAPY OF CERVICAL CANCER(2006)
• In vitro cytotoxicity of cisplatin combined with carboplatin on osteosarcoma cell line OS-732(2004)
• → Inhibitory Effect of Metal Complexes Cisplatin and Carboplatin of Cervical Cancer Cells(2023)